{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-148651","form_type":"8-K","ticker":"ACLX","cik":"0001786205","company_name":"Arcellx, Inc.","filed_at":"2022-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.311993+00:00","generated_at":"2026-06-25T19:01:54.634432+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arcellx Q1 net loss $32.4M; CART-ddBCMA 100% ORR; doses first ACLX-001 patient","bullets":["Q1 net loss $32.4M (vs $11.3M Q1 2021); R&D expense $24.4M (+$15.9M).","Cash and marketable securities $210.9M as of Mar 31; funds operations into H2 2023.","First patient dosed in Phase 1 of ACLX-001 (ARC-SparX) for relapsed/refractory multiple myeloma.","CART-ddBCMA Phase 1 data published in Blood Advances: 100% ORR, 75% CR/sCR.","CART-ddBCMA oral abstract at ASCO June 5; data on ~25 patients to be presented."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-148651","json":"https://secwatch.observer/filing/0001193125-22-148651.json","markdown":"https://secwatch.observer/filing/0001193125-22-148651.md","text":"https://secwatch.observer/filing/0001193125-22-148651.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1786205/000119312522148651/0001193125-22-148651-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1786205/000119312522148651/d338467d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T19:01:54.634432+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}